Last Updated:
10 Mar 2026, 03:29:50 PM (IST)
Krebs Biochemicals & Industries Limited
NSE: KREBSBIO BSE: KREBSBIO
NSE
54.98
2.97 (5.71%)
Prev Close
52.01
Open Price
53.05
Volume
1,382
Today Low / High
52 / 55.89
52 WK Low / High
50.75 / 113.5
Range
52 - 58
BSE
55.11
3.96 (7.74%)
Prev Close
51.15
Open Price
53.88
Volume
1,000
Today Low / High
53.88 / 55.27
52 WK Low / High
50.5 / 113.9
Range
52 - 58
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 54.98 (target range: 52 - 58), reflecting a change of 2.97 (5.71044%). On the BSE, it is listed at 55.11 (target range: 52 - 58), showing a change of 3.96 (7.74194%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Krebs Biochemicals & Industries Limited Graph
Krebs Biochemicals & Industries Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Krebs Biochemicals & Industries Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 54.98, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 55.11 | 55.66 | 50.09 - 61.23 |
| 56.21 | 44.97 - 67.45 | ||
| 56.76 | 39.73 - 73.79 | ||
| Bearish Scenario | 55.11 | 54.56 | 49.10 - 60.01 |
| 54.01 | 43.21 - 64.81 | ||
| 53.46 | 37.42 - 69.49 |
Overview of Krebs Biochemicals & Industries Limited
ISIN
INE268B01013
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
12,701
Market Cap
1,162,115,585
Last Dividend
0
Official Website
IPO Date
2016-10-27
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of KREBSBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2005-09-14 | September 14, 05 | 2.89781 | 3 | 2005-09-16 | 2005-10-01 | 2005-06-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 43.31 Cr | 5.56 Cr | 37.76 Cr | 0.8717 | 1.52 Cr | 0.00 Cr | -21.72 Cr | -26.94 Cr | -12.50 | -14.32 Cr | -0.6220 |
| 2024-03-31 | 50.42 Cr | 61.30 Cr | -10.87 Cr | -0.2157 | 0.00 Cr | 0.60 Cr | -15.49 Cr | -19.73 Cr | -9.15 | -8.27 Cr | -0.3913 |
| 2023-03-31 | 52.13 Cr | 27.72 Cr | 24.42 Cr | 0.4684 | 0.00 Cr | 0.86 Cr | -21.94 Cr | -24.69 Cr | -11.45 | -15.16 Cr | -0.4736 |
| 2022-03-31 | 59.70 Cr | 65.47 Cr | -5.76 Cr | -0.0965 | 1.64 Cr | 1.14 Cr | -39.49 Cr | -44.53 Cr | -20.65 | -32.85 Cr | -0.7458 |
| 2021-03-31 | 38.61 Cr | 52.23 Cr | -13.63 Cr | -0.3529 | 1.47 Cr | 0.67 Cr | -23.67 Cr | -28.36 Cr | -14.45 | -16.96 Cr | -0.7346 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.14 Cr | 169.04 Cr | 315.27 Cr | -146.2388 Cr | 212.21 Cr | 212.07 Cr | 6.03 Cr | 146.47 Cr | 0.00 Cr | 0.00 Cr | 2.85 Cr | 103.5260 Cr |
| 2024-03-31 | 0.14 Cr | 178.17 Cr | 297.39 Cr | -119.2167 Cr | 238.68 Cr | 238.61 Cr | 10.24 Cr | 149.74 Cr | 0.00 Cr | 0.00 Cr | -0.47 Cr | 61.8339 Cr |
| 2023-03-31 | 0.09 Cr | 174.98 Cr | 274.44 Cr | -99.4623 Cr | 183.24 Cr | 183.15 Cr | 12.36 Cr | 149.05 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 49.1047 Cr |
| 2022-03-31 | 0.03 Cr | 189.81 Cr | 264.90 Cr | -75.0932 Cr | 188.10 Cr | 188.07 Cr | 25.86 Cr | 144.93 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 78.0640 Cr |
| 2021-03-31 | 0.71 Cr | 159.22 Cr | 201.95 Cr | -42.7329 Cr | 111.14 Cr | 125.55 Cr | 16.89 Cr | 128.21 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 48.1924 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -7.8910 Cr | -4.9696 Cr | 12.8648 Cr | -11.4542 Cr | 0.0042 Cr | 0.1416 Cr | -3.5632 Cr | -26.9240 Cr | 18.7789 Cr | 0.0000 Cr | 3.7649 Cr |
| 2024-03-31 | 2.3040 Cr | -7.8167 Cr | 5.5641 Cr | -7.0501 Cr | 0.0516 Cr | 0.1374 Cr | -9.4150 Cr | -19.7284 Cr | 10.2535 Cr | 0.0000 Cr | 2.1492 Cr |
| 2023-03-31 | -24.7132 Cr | -12.6450 Cr | 37.3433 Cr | -35.5836 Cr | -0.0148 Cr | 0.0858 Cr | -10.8704 Cr | -24.6919 Cr | 40.3165 Cr | 0.0000 Cr | 13.6170 Cr |
| 2022-03-31 | -17.2162 Cr | -22.8995 Cr | 39.5056 Cr | -40.7363 Cr | -0.6101 Cr | 0.1006 Cr | -23.5201 Cr | -44.5268 Cr | 32.3835 Cr | 0.0000 Cr | -8.9622 Cr |
| 2021-03-31 | -14.5748 Cr | -22.5493 Cr | 37.6605 Cr | -40.0812 Cr | 0.5364 Cr | 0.7107 Cr | -25.5064 Cr | -28.3586 Cr | 33.4906 Cr | 0.0000 Cr | -1.6049 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 7.27 Cr | 0.00 Cr | 7.27 Cr | 0.9998 | -1.34 Cr | -3.13 Cr | -1.45 | 0.30 Cr | -0.4298 |
| 2025-09-30 | 4.17 Cr | 4.32 Cr | -0.15 Cr | -0.0356 | -4.42 Cr | -6.14 Cr | -2.85 | -2.79 Cr | -1.4740 |
| 2025-06-30 | 5.48 Cr | 0.29 Cr | 5.19 Cr | 0.9472 | -3.69 Cr | -5.32 Cr | -2.47 | -2.08 Cr | -0.9714 |
| 2025-03-31 | 6.10 Cr | 0.57 Cr | 5.53 Cr | 0.9071 | -6.98 Cr | -8.27 Cr | -3.84 | -5.07 Cr | -1.3554 |
| 2024-12-31 | 11.47 Cr | 1.31 Cr | 10.16 Cr | 0.8858 | -6.43 Cr | -7.74 Cr | -3.59 | -4.46 Cr | -0.6749 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 0.15 Cr | 0.00 Cr | 0.15 Cr | 0.05 Cr | 5.77 Cr | 9.78 Cr | 143.54 Cr | 165.91 Cr | 326.75 Cr |
| 2025-09-30 | 0.13 Cr | 0.03 Cr | 0.13 Cr | 0.14 Cr | 5.77 Cr | 10.17 Cr | 145.39 Cr | 168.03 Cr | 325.74 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 146.24 Cr |
| 2025-03-31 | 0.14 Cr | 0.20 Cr | 0.34 Cr | 0.05 Cr | 6.03 Cr | 10.26 Cr | 146.47 Cr | 169.04 Cr | 315.27 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 130.15 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -5.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -8.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -7.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -5.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -5.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-01-31 | January 31, 19 | 207:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
MD, Chief Executive Officer & Director
Manish Kumar Jain
Gender: male
Year Born: 1976
Company Secretary & Compliance Officer
Rakesh Kalbate
Gender: male
Year Born:
Chief Financial Officer
Ritesh Jain
Gender: male
Year Born:
FAQs about Krebs Biochemicals & Industries Limited
Who is the CEO of the company?
The CEO is Manish Kumar Jain.
What is the current market price of the stock?
The current price is ₹53.90.
What is the 52-week price range?
The range is ₹53.05-113.5.
What is the market capitalization of the company?
The market capitalization is ₹116.21 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -5.08.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Krebs Biochemicals & Industries Limited (ISIN: INE268B01013) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹116.21 crores and an average daily volume of 12,701 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.